In a filing, Viridian Therapeutics Inc revealed its Director Fairmount Funds Management LLC acquired Company’s shares for reported $10.0 million on Oct 23 ’25. In the deal valued at $22.00 per share,454,545 shares were bought. As a result of this transaction, Fairmount Funds Management LLC now holds 3,914,458 shares worth roughly $88.23 million.
A number of analysts have revised their coverage, including Wells Fargo’s analysts, who decreased its forecast for the stock in mid December from “an Overweight” to “an Equal weight”. TD Cowen began covering VRDN with “Buy” recommendation on November 25, 2024. Needham maintained its rating on September 11, 2024. It rated VRDN as “a Buy”.
Price Performance Review of VRDN
On Monday, Viridian Therapeutics Inc [NASDAQ:VRDN] saw its stock jump 1.71% to $22.54. Over the last five days, the stock has lost -6.43%. Viridian Therapeutics Inc shares have fallen nearly -3.63% since the year began. Nevertheless, the stocks have risen 17.58% over the past one year. While a 52-week high of $27.20 was reached on 10/20/25, a 52-week low of $9.90 was recorded on 04/09/25.
Levels Of Support And Resistance For VRDN Stock
The 24-hour chart illustrates a support level at 21.98, which if violated will result in even more drops to 21.43. On the upside, there is a resistance level at 23.22. A further resistance level may holdings at 23.90.
How much short interest is there in Viridian Therapeutics Inc?
A steep rise in short interest was recorded in Viridian Therapeutics Inc stocks on 2025-10-15, dropping by -1.01 million shares to a total of 9.99 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-15 was 11.0 million shares. There was a decline of -10.15%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 11, 2024 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $29 price target.
